AU631888B2 - New imipramine-based compositions - Google Patents

New imipramine-based compositions Download PDF

Info

Publication number
AU631888B2
AU631888B2 AU57433/90A AU5743390A AU631888B2 AU 631888 B2 AU631888 B2 AU 631888B2 AU 57433/90 A AU57433/90 A AU 57433/90A AU 5743390 A AU5743390 A AU 5743390A AU 631888 B2 AU631888 B2 AU 631888B2
Authority
AU
Australia
Prior art keywords
document
international
date
cyclodextrin
imipramine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57433/90A
Other languages
English (en)
Other versions
AU5743390A (en
Inventor
Anne Coutel-Egros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Sante SA
Original Assignee
Rhone Poulenc Sante SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante SA filed Critical Rhone Poulenc Sante SA
Publication of AU5743390A publication Critical patent/AU5743390A/en
Application granted granted Critical
Publication of AU631888B2 publication Critical patent/AU631888B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU57433/90A 1989-05-24 1990-05-22 New imipramine-based compositions Ceased AU631888B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation
FR8906781 1989-05-24

Publications (2)

Publication Number Publication Date
AU5743390A AU5743390A (en) 1990-12-18
AU631888B2 true AU631888B2 (en) 1992-12-10

Family

ID=9381955

Family Applications (2)

Application Number Title Priority Date Filing Date
AU57433/90A Ceased AU631888B2 (en) 1989-05-24 1990-05-22 New imipramine-based compositions
AU55828/90A Ceased AU623779B2 (en) 1989-05-24 1990-05-22 New porus pharmaceutical form and its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU55828/90A Ceased AU623779B2 (en) 1989-05-24 1990-05-22 New porus pharmaceutical form and its preparation

Country Status (24)

Country Link
US (1) US5244881A (forum.php)
EP (2) EP0399902B1 (forum.php)
JP (1) JP2948271B2 (forum.php)
KR (1) KR0163423B1 (forum.php)
AT (2) ATE83663T1 (forum.php)
AU (2) AU631888B2 (forum.php)
CA (2) CA2017360A1 (forum.php)
DD (1) DD297915A5 (forum.php)
DE (2) DE69000641T2 (forum.php)
DK (2) DK0399902T3 (forum.php)
ES (2) ES2054289T3 (forum.php)
FI (1) FI103712B1 (forum.php)
FR (1) FR2647343B1 (forum.php)
GR (1) GR3006655T3 (forum.php)
IE (2) IE64370B1 (forum.php)
IL (2) IL94460A0 (forum.php)
NO (1) NO180517C (forum.php)
NZ (2) NZ233766A (forum.php)
PL (1) PL285327A1 (forum.php)
PT (2) PT94139B (forum.php)
TW (1) TW257672B (forum.php)
WO (1) WO1990014089A1 (forum.php)
YU (1) YU100790A (forum.php)
ZA (2) ZA903895B (forum.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
KR100256147B1 (ko) 1991-12-24 2000-08-01 오노다 마사요시 구강내 붕해성 제제 및 이의 제조방법
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
CA2190598A1 (en) * 1994-05-27 1995-12-07 Lawrence John Penkler Pharmaceutical composition
US6471992B1 (en) * 1997-02-20 2002-10-29 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
JP4644364B2 (ja) * 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
PL212123B1 (pl) 2002-01-15 2012-08-31 Ucb Farchim Sa Doustna kompozycja farmaceutyczna
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
HUP0500134A3 (en) 2002-02-25 2009-12-28 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US8293804B2 (en) 2007-04-13 2012-10-23 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
EA201070544A1 (ru) 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
BRPI0918906A2 (pt) * 2008-09-05 2015-12-01 Mcneil Ppc Inc método para a produção de comprimidos de cetirizina
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2012037117A1 (en) * 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (forum.php) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
WO1986003198A1 (en) * 1984-11-27 1986-06-05 Dainippon Pharmaceutical Co., Ltd. 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
CA2017355A1 (fr) 1990-11-24
AU5743390A (en) 1990-12-18
ATE83663T1 (de) 1993-01-15
ES2054289T3 (es) 1994-08-01
FI902553A0 (fi) 1990-05-23
AU5582890A (en) 1991-01-10
US5244881A (en) 1993-09-14
DK0399902T3 (da) 1994-02-14
ES2062437T3 (es) 1994-12-16
DE69000641T2 (de) 1993-06-09
PT94139A (pt) 1991-01-08
DD297915A5 (de) 1992-01-30
DE69005359T2 (de) 1994-05-05
JPH0356412A (ja) 1991-03-12
PL285327A1 (en) 1991-02-11
KR900017570A (ko) 1990-12-19
IE64370B1 (en) 1995-07-26
DE69000641D1 (de) 1993-02-04
AU623779B2 (en) 1992-05-21
IL94459A0 (en) 1991-03-10
NZ233784A (en) 1993-04-28
IE901821L (en) 1990-11-24
DK0399903T3 (da) 1993-02-08
YU100790A (en) 1992-05-28
FR2647343B1 (fr) 1994-05-06
EP0399902B1 (fr) 1993-12-22
IL94459A (en) 1995-01-24
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
IL94460A0 (en) 1991-03-10
PT94138B (pt) 1996-12-31
EP0399903B1 (fr) 1992-12-23
NO902280L (no) 1990-11-26
NO180517C (no) 1997-05-07
IE901862L (en) 1990-11-24
NO180517B (no) 1997-01-27
PT94138A (pt) 1991-01-08
ATE98867T1 (de) 1994-01-15
PT94139B (pt) 1996-12-31
WO1990014089A1 (fr) 1990-11-29
TW257672B (forum.php) 1995-09-21
EP0399903A1 (fr) 1990-11-28
DE69005359D1 (de) 1994-02-03
NO902280D0 (no) 1990-05-23
FI103712B1 (fi) 1999-08-31
ZA903978B (en) 1991-03-27
IE63317B1 (en) 1995-04-05
ZA903895B (en) 1991-03-27
FR2647343A1 (fr) 1990-11-30
NZ233766A (en) 1991-08-27
JP2948271B2 (ja) 1999-09-13
KR0163423B1 (ko) 1998-12-01
GR3006655T3 (forum.php) 1993-06-30
CA2017360A1 (fr) 1990-11-24

Similar Documents

Publication Publication Date Title
AU631888B2 (en) New imipramine-based compositions
Sellers et al. Drug kinetics and alcohol ingestion
EP1496866B1 (en) Process for preparing tannate liquid and semi-solid dosage forms
Custódio et al. The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes
JPH0655722B2 (ja) 医薬用組成物
JPH05504783A (ja) 水溶解性の高いシクロデキストリン誘導体組成物及びその用途
JPS63310832A (ja) エリスロマイシン含有組成物
JPS60188035A (ja) ステビオサイドの呈味改善法
Hoener et al. Nitrofurantoin disposition
Davies et al. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor
US5100878A (en) Blocking the effect of teratogens on a fetus
Yayehrad et al. Physicochemical characterization and evaluation of Ficus vasta gum as a binder in tablet formulation
Köpf-Maier et al. Antitumor activity of titanocene amino acid complexes
Gonthier et al. Development of an ELISA for pantothenic acid (vitamin B5) for application in the nutrition and biological fields
EFSA Panel on Food Additives and Nutrient Sources Added to Food Scientific Opinion on the re‐evaluation of Quinoline Yellow (E 104) as a food additive
NL7905258A (nl) Spiroketalinen en hun toepassingen.
Kadam et al. Development and evaluation of oral controlled release chlorpheniramine-ion exchange resinate suspension
Tolstikova et al. Complex of nifedipine with glycyrrhizic acid as a novel water-soluble antihypertensive and antiarrhythmic agent
JPH04506362A (ja) Ｎ―エトキシカルボニル―３―モルホリノ―シドノンイミン又はその塩の、シクロデキストリン誘導体を用いて形成される包接錯体、それらの製造法及び該錯体を含有する医薬組成物
JPH04506221A (ja) ３―モルホリノ―シドノンイミン又はその塩又はその互変異性体の包接錯体、その製法、及び該包接錯体を含有する医薬組成物
Hewitt et al. Effect of viscosity on thiamine and riboflavin absorption in man
AU626074B2 (en) Use of dextrin derivatives for the treatment of acidic conditions
Kane et al. Characterization of model antigens composed of biotinylated haptens bound to avidin
Aigner et al. Increasing the solubility characteristics of fenofibrate with cyclodextrin
Belal et al. Colorimetric acetaminophen determination in pharmaceutical formulations